Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by Meno111on Nov 05, 2018 6:34pm
188 Views
Post# 28927446

RE:RE:earnings

RE:RE:earnings'm telling yea its going to be a net income. Not because of operations but because of non-operating income.

EPS .50+ and that's not including rev from biological assets. If you want a clear visualization of what happened in the quarter. The cash flow statement is the way. It removes all the clutter that occured from unrealized gains/losses, non-cash items etc.

Also.....

july-sept

Rev: $52.50m
COGS: ($24.28m)
Operating: ($45m) removed non-cash items and added 15% from june 30 amount
Working Capital: ($125m), a/r,ba,inv,prepaid budget
Total= ($141.78m)

oct-dec

Rev: $155m
COGS: ($77.62m)
Operating: ($52m) 
Working Capital: ($125m)
Total: ($99.62m)


Operating: $241.40m
Investing: $300m
Financing: $600m

Assets: 6210.60m
Liabilities: (310m)
s/o: 350m

$5910.60m/350m= 16.89 book value
@5x = $84.46

The figures by the year end will not be the same as the ones stated above. However, as long as the book value and share price is above 16.89 and $84.46 respectively, I would be satisfied with the result.

Although, the question of whether it was because of fundamentals or other factors will be up for debate.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse